

Furthermore, solely to ensure a complete response, Applicants elect the species (3a*R*, 6a*S*)-*N*-[(1*S*)-1-(4-Benzoyl-6-oxo-hexahydro-pyrrolo[3,2-*b*] pyrrole-1-carbonyl)-3-methyl-butyl]-4-piperazin-1-ylbenzamide (shown in Example 194 of the present application). It is believed that at least claims 1-8, 13-16, 18-28, 30, 31, 33, 35, 37, 49, 51, 52, 58, and 60-74 read on the elected species.

The election of Group II and the elected species is being made solely to comply with the Restriction Requirement and the right to file divisional applications on non-elected subject matter is reserved.

Conclusion

Early and favorable consideration of the application is earnestly solicited.

Applicants request any further extension of time necessary for response. The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 2062 (240671).

Date: October 16, 2007

/Mark D. Russett/

Mark D. Russett, Reg. No. 41,281
EDWARDS ANGELL PALMER & DODGE LLP
P. O. Box 55874
Boston, MA 02205
Tel: (617) 239-0100
Fax: (617) 439-4170